Histocell
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | 1.2m | 2.0m | 2.4m | 2.7m |
| % growth | 43 % | 9 % | (10 %) | 204 % | 59 % | 22 % | 13 % |
| EBITDA | (<1m) | (1.2m) | (1.5m) | (<1m) | <1m | 1.2m | - |
| % EBITDA margin | (187 %) | (265 %) | (365 %) | (58 %) | 2 % | 49 % | - |
| Profit | (1.4m) | (1.9m) | (2.5m) | (1.5m) | (<1m) | <1m | - |
| % profit margin | (337 %) | (419 %) | (613 %) | (120 %) | (38 %) | 17 % | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $450k | Grant | |
| N/A | €2.5m | Early VC | |
€50.0k | Grant | ||
* | N/A | Late VC | |
| Total Funding | AUD5.0m | ||
Related Content
Recent News about Histocell
EditHistocell is a pioneering company in the field of regenerative medicine, focusing on the development of advanced therapy medicinal products, medical devices, and dermocosmetics. The company operates primarily in the healthcare and pharmaceutical markets, serving a diverse range of clients including hospitals, clinics, and skincare professionals.
Histocell's core business revolves around the use of mesenchymal stem cells, which are specialized cells with enhanced therapeutic capabilities. These cells are used in their flagship product, HC016, which is currently undergoing clinical trials for treating Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19, as well as for acute spinal cord and lung injuries. This highlights the company's commitment to addressing critical health issues through innovative treatments.
In addition to its advanced therapy products, Histocell also offers a range of medical devices aimed at wound healing and skin care. Their wound care solutions, such as Reoxcare, are designed to treat damaged skin and chronic wounds, providing significant benefits to patients with long-term skin conditions.
The company also produces high-quality dermocosmetic products under the brand Histoessence, which includes pharmaceutical-grade active ingredients for skincare. These products cater to consumers looking for effective skincare solutions backed by scientific research.
Histocell's business model is multifaceted. It generates revenue through the sale of its advanced therapy medicinal products, medical devices, and dermocosmetics. Additionally, the company engages in third-party manufacturing, leveraging its two certified facilities in Spain to produce medical devices and dermocosmetic products for other companies.
In summary, Histocell is a dynamic player in the regenerative medicine market, dedicated to improving people's quality of life through innovative therapies and high-quality skincare products.
Keywords: Regenerative Medicine, Stem Cells, ARDS, COVID-19, Wound Healing, Skincare, Clinical Trials, Medical Devices, Dermocosmetics, Healthcare.